Open-label Study to Assess Reduction of Background Asthma Medication While Sustaining Asthma Control and Clinical Remission With Tezepelumab in Patients 12-80yrs With Severe Asthma. (ARRIVAL)

A Multicentre, Randomised, Open-Label, Parallel-Group, Phase IIIb Study to Assess the Potential for Tezepelumab-treated Patients With Severe Asthma to Reduce Background Therapy While Sustaining Asthma Control and Clinical Remission

The objective of this study is to assess the potential for tezepelumab-treated patients (subcutaneous administration) to reduce maintenance therapy without loss of asthma control in adolescent and adults with severe asthma..

Study details include:

1. The study duration will be up to 72 weeks.
2. The treatment duration will be up to 68 weeks.
3. The visit frequency will be once every 4 weeks (Q4W).

Study Overview

• Status: Active, not recruiting
• Conditions: Severe Asthma
• Intervention / Treatment: Combination product: Tezepelumab; Combination product: Budesonide/formoterol; Combination product: Albuterol/budesonide (AIRSUPRA®); Combination product: Mannitol; Combination product: Salbutamol

Detailed Description

This is a multicentre, randomised, open-label, parallel-group, phase IIIb study to assess the potential for tezepelumab-treated patients to (1) reduce maintenance therapy without the loss of asthma control at Week 56, among those who demonstrated asthma control or low biomarkers at Week 24, and (2) be in asthma control and have characteristics of clinical remission at Week 24.

Approximately 65 sites in 10 countries will enrol adult and adolescent patients with severe uncontrolled asthma.

The study is divided into 5 phases as described below:

• Screening/Run-in Phase (from Week -4 until Week 0, up to 4 Weeks)
• Treatment Induction Phase (Week 0 to Week 4)
• Treatment Continuation Phase (Week 4 to Week 24)
• Tezepelumab Treatment With or Without ICS Step-down Therapy Phase (Week 24 to Week 56)
• Maintenance Phase (Week 56 to Week 72)

• Study Type: Interventional
• Enrollment (Actual): 326
• Phase: Phase 3

Contacts and Locations

Study Locations

• Argentina
  • Berazategui, Argentina, 1104
    • Research Site
  • CABA, Argentina, C1012AAR
    • Research Site
  • Concepción del Uruguay, Argentina, 3260
    • Research Site
  • Mendoza, Argentina, 5500
    • Research Site
  • Mendoza, Argentina, M5500CCG
    • Research Site
  • Quilmes, Argentina, B1878FNR
    • Research Site
  • Rosario, Argentina, 2000
    • Research Site
  • Rosario, Argentina, 2002
    • Research Site
  • San Miguel de Tucumán, Argentina, 4000
    • Research Site
  • Santa Fe, Argentina, 3000
    • Research Site
• Belgium
  • Anderlecht, Belgium, 1070
    • Research Site
  • Edegem, Belgium, 2650
    • Research Site
  • Erpent, Belgium, 5101
    • Research Site
  • Ghent, Belgium, 9000
    • Research Site
  • Liège, Belgium, 4000
    • Research Site
• Bulgaria
  • Haskovo, Bulgaria, 6300
    • Research Site
  • Pleven, Bulgaria, 5804
    • Research Site
  • Razgrad, Bulgaria, 7200
    • Research Site
  • Rousse, Bulgaria, 7002
    • Research Site
  • Sofia, Bulgaria, 1431
    • Research Site
  • Sofia, Bulgaria, 1154
    • Research Site
  • Stara Zagora, Bulgaria, 6003
    • Research Site
  • Velika Tarnovo, Bulgaria, 5250
    • Research Site
• Canada
  • British Columbia
    • Vancouver, British Columbia, Canada, V5Z 1M9
      • Research Site
  • Ontario
    • Ajax, Ontario, Canada, L1S 2J5
      • Research Site
    • Windsor, Ontario, Canada, N8X 1T3
      • Research Site
  • Quebec
    • Québec, Quebec, Canada, G1V 4G5
      • Research Site
    • Sherbrooke, Quebec, Canada, J1H 5N4
      • Research Site
  • Saskatchewan
    • Regina, Saskatchewan, Canada, S7N 5A2
      • Research Site
• Denmark
  • Aalborg, Denmark, 9000
    • Research Site
  • Hvidovre, Denmark, 2650
    • Research Site
  • Svendborg, Denmark, 5700
    • Research Site
  • Vejle, Denmark, 7100
    • Research Site
• France
  • Créteil, France, 94000
    • Research Site
  • La Tronche, France, 38700
    • Research Site
  • Lyon, France, 69004
    • Research Site
  • Marseille, France, 13915
    • Research Site
  • Montpellier, France, 34295
    • Research Site
  • Strasbourg, France, 67091
    • Research Site
• Germany
  • Augsburg, Germany, 86150
    • Research Site
  • Bonn, Germany, 53127
    • Research Site
  • Cottbus, Germany, 03050
    • Research Site
  • Hanover, Germany, 30625
    • Research Site
  • Mainz, Germany, 55128
    • Research Site
• Italy
  • Florence, Italy, 50134
    • Research Site
  • Orbassano, Italy, 10043
    • Research Site
  • Roma, Italy, 00168
    • Research Site
  • Roma, Italy, 00161
    • Research Site
  • Verona, Italy, 37134
    • Research Site
• Mexico
  • Chihuahua City, Mexico, 31200
    • Research Site
  • Cuauhtémoc, Mexico, 06700
    • Research Site
  • Monterrey, Mexico, 64360
    • Research Site
• Spain
  • Badalona(Barcelona), Spain, 08916
    • Research Site
  • Barcelona, Spain, 08035
    • Research Site
  • Lugo, Spain, 27002
    • Research Site
  • Madrid, Spain, 28041
    • Research Site
  • Madrid, Spain, 28040
    • Research Site
  • Madrid, Spain, 28006
    • Research Site
• United Kingdom
  • Belfast, United Kingdom, BT9 7BL
    • Research Site
  • Liverpool, United Kingdom, L7 8XP
    • Research Site
  • London, United Kingdom, SE1 9RT
    • Research Site
  • Southampton, United Kingdom, SO16 6YD
    • Research Site
• United States
  • California
    • Palmdale, California, United States, 93551
      • Research Site
  • Colorado
    • Colorado Springs, Colorado, United States, 80907
      • Research Site
  • Florida
    • Miami, Florida, United States, 33136
      • Research Site
  • Massachusetts
    • Boston, Massachusetts, United States, 02115
      • Research Site
  • Missouri
    • St Louis, Missouri, United States, 63110
      • Research Site
  • New Jersey
    • New Brunswick, New Jersey, United States, 08901
      • Research Site
  • Oklahoma
    • Oklahoma City, Oklahoma, United States, 73120
      • Research Site
  • Texas
    • McAllen, Texas, United States, 78503
      • Research Site

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Child; Adult; Older Adult
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria at Visit 1 (Screening):

Informed Consent

1. Provision of signed and dated written ICF prior to any mandatory study-specific procedures, sampling, and analyses for patients who are at or over the age of majority (as per local law). For patients who are less than the age of majority, in addition to providing their informed consent, the patients' legally authorised representative must also provide their informed assent (Appendix A 3).

   Age

2. Patients must be 12 to 80 years of age inclusive, at the time of signing the ICF.

   Type of Patient and Disease Characteristics

3. Documented medical record history for at least 12 months prior to Visit 1.

4. Documented physician-diagnosed severe asthma within 10 years prior to Visit 1 (ie, severe asthma was not diagnosed more than 10 years prior) consisting of any of the following:

   1. FEV1 > 12% reversibility, OR
   2. Evidence of airflow variability (to show that lung function is altered over time): FEV1 ≥ 400 mL variability over time, OR
   3. Challenge tests that are positive on one of the below:

   (i) Methacholine - PD20 ≤ 8 mg/mL (ii) Mannitol - PD15 15% drop on FEV1 out of dose < than 635 mg of inhaled mannitol (iii) Exercise - 10% fall of FEV1

5. ACQ-5 ≥ 1.5 and < 3.

6. History of physician-diagnosed asthma that requires continuous treatment with high-dose ICS (as defined by GINA or highest approved dose per posology per country) plus a LABA for at least 6 months prior to Visit 1 (Appendix I). The ICS and LABA can be contained within a combination product or given by separate inhalers.

   Note: Additional maintenance asthma controller medications (eg, LTRAs, tiotropium, cromone, theophylline) are allowed.

7. Pre-brochodilator FEV1 > 60% predicted and evidence of FEV1 reversibility of > 12% within 6 months prior to screening or at screening. Patients with normal lung function (FEV1 > 80%) need evidence of airflow variability as per inclusion criterion 4.

8. Documented history of at least one asthma exacerbation requiring OCS bursts or requiring hospitalization within 12 months prior to Visit 1. An asthma exacerbation will be defined as a worsening of asthma symptoms that leads to any of the following:

   1. A temporary bolus/burst of systemic corticosteroids for at least 3 consecutive days to treat symptoms of asthma worsening; a single depo-injectable dose of corticosteroids will be considered equivalent to a 3-day bolus/burst of systemic corticosteroids
   2. Or, an ER visit (defined as evaluation and treatment for < 24 hours in ER) due to asthma that required systemic corticosteroids (as per above)
   3. Or, an in-patient hospitalisation (defined as admission to an inpatient facility and/or evaluation and treatment in a healthcare facility for ≥ 24 hours).

   Sex and Contraceptive/Barrier Requirements

9. Male or female.

   Female patients:

   • Contraceptive use by women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies. Women of nonchildbearing potential are defined as women who are either permanently sterilised (hysterectomy, bilateral oophorectomy, or bilateral salpingectomy) or who are postmenopausal. Women will be considered postmenopausal if they have been amenorrhoeic for 12 months prior to the planned start date of the induction phase without an alternative medical cause.

   • The following age-specific requirements apply:

     • Women < 50 years old would be considered postmenopausal if they have been amenorrhoeic for 12 months or more following cessation of exogenous hormonal treatment and follicle-stimulating hormone levels in the postmenopausal range.
     • Women ≥ 50 years old would be considered postmenopausal if they have been amenorrhoeic for 12 months or more following cessation of all exogenous hormonal treatment.
     • Adolescents: if patient is female and has reached menarche or has reached Tanner stage 3 breast development (even if not having reached menarche), the patient will be considered a WOCBP.

10. WOCBP must be willing to use one of the methods of contraception described hereafter, from the time of signing the ICF throughout the study and 16 weeks after last tezepelumab administration:

    • Combined (oestrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation: oral, intravaginal, transdermal
    • Progestogen-only hormonal contraception associated with inhibition of ovulation: oral, injectable, implantable
    • Intrauterine device
    • Intrauterine hormone-releasing system
    • Bilateral tubal occlusion
    • Vasectomised partner (vasectomised partner is a highly effective birth control method provided that the partner is the sole sexual partner of the WOCBP patient and that the vasectomised partner has received medical assessment of the surgical success)
    • Sexual abstinence: it is considered a highly effective method only if defined as refraining from heterosexual intercourse during the entire period of risk associated with the study treatments. The reliability of sexual abstinence needs to be evaluated in relation to the duration of the study and the preferred and usual lifestyle of the patient.
    • Cessation of contraception after this point should be discussed with a responsible physician

    Inclusion Criteria 5.1.2 Treatment Induction Phase at Visit 2 (Week 0):

    Before dosing with tezepelumab at Week 0, patients should fulfil the following criteria:

11. ACQ-5 ≥ 1.5 and < 3.
12. Demonstrated proper inhaler technique (patients with improper technique at screening may be trained during screening, but must demonstrate proper technique before enrollment).
13. No excessive SABA use (should be < 5 puffs/day) or for patients using SMART therapy outside the US, no excessive use of SYMBICORT (should be ≤ 8 inhalations/day) or for US patients, no excessive use of AIRSUPRA (should be ≤ 12 inhalations/day).

Exclusion Criteria:

Medical Conditions

1. Any clinically important pulmonary disease other than asthma (eg, active lung infection, chronic obstructive pulmonary disease, bronchiectasis, pulmonary fibrosis, cystic fibrosis, hypoventilation syndrome associated with obesity, lung cancer, alpha 1 anti-trypsin deficiency, and primary ciliary dyskinesia) or pulmonary or systemic diseases, other than asthma, that are associated with elevated peripheral EOS counts (eg, allergic bronchopulmonary aspergillosis/mycosis, Churg-Strauss syndrome, hypereosinophilic syndrome).

2. Any disorder, including, but not limited to, cardiovascular, gastrointestinal, hepatic, renal, neurological, musculoskeletal, infectious, endocrine, metabolic, haematological, psychiatric, or major physical impairment that is not stable in the opinion of the investigator and could:

   • Affect the safety of the patient throughout the study
   • Influence the findings of the study or the interpretation
   • Impede the patient's ability to complete the entire duration of study.
3. A helminth parasitic infection diagnosed within 6 months prior to Visit 1 that has not been treated with, or has failed to respond to, standard of care therapy.
4. Current smokers or patients with smoking history ≥ 10 pack-years and patients using vaping products, including electronic cigarettes. Former smokers with a smoking history of < 10 pack-years and users of vaping or e-cigarette products must have stopped for at least 6 months prior to Visit 1 to be eligible.
5. History of chronic alcohol or drug abuse within 12 months prior to Visit 1.
6. Tuberculosis requiring treatment within the 12 months prior to Visit 1.
7. History of known immunodeficiency disorder including a positive human immunodeficiency virus test at Visit 1, or the patient taking antiretroviral medications as determined by medical history and/or patient's verbal report.
8. Major surgery within 8 weeks prior to Visit 1 or planned surgical procedures requiring general anaesthesia or inpatient status for > 1 day during the conduct of the study.

9. Evidence of COVID-19 within 4 weeks prior to screening or ongoing clinically significant COVID-19 sequelae.

   Prior/Concomitant Therapy

10. Receipt of any marketed or investigational biologic agent within 4 months or 5 half-lives (whichever is longer) prior to Visit 1 or receipt of any investigational nonbiologic agent within 30 days or 5 half-lives (whichever is longest) prior to Visit 1.
11. OCS-dependent patients (received chronic OCS therapy [prednisone ≥ 5 mg/day or equivalent]) for at least 3 months preceding Visit 1.
12. Daily use of maintenance corticosteroids for any reason.
13. Treatment with systemic immunosuppressive/immunomodulating drugs (eg, methotrexate, cyclosporine, etc.), except for OCS used in the treatment of asthma/asthma exacerbations, within the last 12 weeks or 5 half-lives (whichever is longer) prior to Visit 1.
14. Receipt of immunoglobulin or blood products within 30 days prior to Visit 1.
15. Receipt of live attenuated vaccines 30 days prior to the date of Visit 1 and during the study.

16. Patients that have been treated with bronchial thermoplasty in the last 12 months prior to Visit 1.

    Prior/Concurrent Clinical Study Experience

17. Known history of sensitivity to any component of the tezepelumab formulation or a history of drug or other allergy that, in the opinion of the investigator or medical monitor, contraindicates their participation.
18. History of anaphylaxis or documented immune complex disease (Type III hypersensitivity reactions) following any biologic therapy.

19. Concurrent enrolment in another clinical study involving an IMP.

    Diagnostic Assessments

20. Any clinically meaningful abnormal finding in physical examination, haematology, clinical chemistry at Visit 1 which, in the opinion of the investigator, may put the patient at risk because of his/her participation in the study, or may influence the results of the study, or the patient's ability to complete the entire duration of the study.
21. Evidence of active liver disease, including jaundice or AST, ALT, or ALP > 2 times the ULN at Visit 1.

22. Positive hepatitis B surface antigen, hepatitis C virus antibody serology at screening, or a positive medical history for hepatitis B or C. Patients with a history of hepatitis B vaccination without a history of hepatitis B are allowed to participate.

    Other Exclusions

23. Involvement in the planning and/or conduct of the study (applies to AstraZeneca staff and/or site staff), or patients employed by or relatives of the employees of the site or AstraZeneca.
24. Judgement by the investigator that the patient should not participate in the study if the patient is unlikely to comply with study procedures, restrictions, and requirements.
25. For women only: Pregnant, breastfeeding, or lactating women. A serum β-HCG pregnancy test must be drawn for WOCBP at the screening visit. If the results of the serum β-HCG cannot be obtained prior to dosing of the IMP, a patient may be enrolled on the basis of a negative urine pregnancy test, though serum β-HCG must still be obtained. If either test is positive, the patient should be excluded. Since urine and serum tests may miss a pregnancy in the first days after conception, relevant menstrual history and sexual history, including methods of contraception, should be considered. Any patient whose menstrual and/or sexual history suggests the possibility of early pregnancy should be excluded.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

3

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Group 1 - Asthma Control or Low Biomarkers - Step-down of ICS; Asthma Control or Low Biomarkers - Step-down of ICS. Only patients with asthma control or low biomarkers at Week 24 will be randomized into Group 1 or 2	Combination product: Tezepelumab; IMP. Subcutaneous injection. Unit dose strengths 210 mg.; Other Names: TEZSPIRE®; Combination product: Budesonide/formoterol; AxMP. Oral inhalation. High-dose: 160 μg/4.5 μg per inhalation; Medium and Low-dose: 80 μg/4.5 μg per inhalation; Other Names: SYMBICORT® pMDI; Combination product: Albuterol/budesonide (AIRSUPRA®); AxMP. Oral inhalation. Reliever only. Unit dose strengths 90 μg/80 μg per inhalation In US only.; Other Names: AIRSUPRA®; Combination product: Mannitol; NIMP. Oral nebulization. Unit dose strengths: Graduated doses of 0 mg, 5 mg, 10 mg, 20 mg and 40 mg capsules; Other Names: ARIDOL®; Combination product: Salbutamol; AxMP. Used outside the US only. Oral inhalation. Unit dose strengths: 100 μg per inhalation; Other Names: Sabumalin, albuterol, ventolin HFA, Proair HFA, Proventil HFA
Experimental: Group 2 - Asthma Control or Low Biomarkers - No Step-down of ICS; Asthma Control or Low Biomarkers - No Step-down of ICS. Only patients with asthma control or low biomarkers at Week 24 will be randomized into Group 1 or 2	Combination product: Tezepelumab; IMP. Subcutaneous injection. Unit dose strengths 210 mg.; Other Names: TEZSPIRE®; Combination product: Budesonide/formoterol; AxMP. Oral inhalation. High-dose: 160 μg/4.5 μg per inhalation; Medium and Low-dose: 80 μg/4.5 μg per inhalation; Other Names: SYMBICORT® pMDI; Combination product: Albuterol/budesonide (AIRSUPRA®); AxMP. Oral inhalation. Reliever only. Unit dose strengths 90 μg/80 μg per inhalation In US only.; Other Names: AIRSUPRA®; Combination product: Mannitol; NIMP. Oral nebulization. Unit dose strengths: Graduated doses of 0 mg, 5 mg, 10 mg, 20 mg and 40 mg capsules; Other Names: ARIDOL®; Combination product: Salbutamol; AxMP. Used outside the US only. Oral inhalation. Unit dose strengths: 100 μg per inhalation; Other Names: Sabumalin, albuterol, ventolin HFA, Proair HFA, Proventil HFA
Experimental: Group 3 - No Asthma Control or Low Biomarkers - No Step-down of ICS; No Asthma Control or Low Biomarkers - No Step-down of ICS	Combination product: Tezepelumab; IMP. Subcutaneous injection. Unit dose strengths 210 mg.; Other Names: TEZSPIRE®; Combination product: Budesonide/formoterol; AxMP. Oral inhalation. High-dose: 160 μg/4.5 μg per inhalation; Medium and Low-dose: 80 μg/4.5 μg per inhalation; Other Names: SYMBICORT® pMDI; Combination product: Albuterol/budesonide (AIRSUPRA®); AxMP. Oral inhalation. Reliever only. Unit dose strengths 90 μg/80 μg per inhalation In US only.; Other Names: AIRSUPRA®; Combination product: Mannitol; NIMP. Oral nebulization. Unit dose strengths: Graduated doses of 0 mg, 5 mg, 10 mg, 20 mg and 40 mg capsules; Other Names: ARIDOL®

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Proportion of patients who reduced their SYMBICORT® daily maintenance dose without the loss of asthma control at the end of the step-down phase.	Proportion of patients who reduced their SYMBICORT® daily maintenance dose without the loss of asthma control at the end of the step-down phase to either: Outside of the US: Medium-dose maintenance and reliever therapy, or; Low-dose maintenance and reliever therapy, or; SYMBICORT® anti-inflammatory reliever only In the US: Medium-dose SYMBICORT® and AIRSUPRA®,or; Low-dose SYMBICORT® and AIRSUPRA®, or; AIRSUPRA® only	Week 56

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Proportion of patients in asthma control	Proportion of patients in asthma control at Week24.	Week 24
Proportion of patients with characteristics of clinical remission	Proportion of patients with characteristics of clinical remission at Week 24	Week 24
Proportion of patients in asthma control at Week 56 among those in asthma control at Week 24	Proportion of patients in asthma control at Week 56 among those in asthma control at Week 24; summarised separately for patients randomised to ICS step-down and for patients randomised to no step-down of ICS.	Week 56
Proportion of patients in asthma control at Week 72 among those in asthma control at Week 24	Proportion of patients in asthma control at Week 72 among those in asthma control at Week 24; summarised separately for patients randomised to ICS step-down and for patients randomised to no step-down of ICS.	Week 72
Proportion of patients in asthma control at both Week 56 and Week 72 among those in asthma control at Week 24	Proportion of patients in asthma control at both Week 56 and Week 72 among those in asthma control at Week 24; summarised separately for patients randomised to ICS step-down and for patients randomised to no step-down of ICS.	Week 56 and Week 72
Proportion of patients in asthma control at Week 56 among those who demonstrated neither asthma control nor low biomarkers at Week 24	Proportion of patients in asthma control at Week 56 among those who demonstrated neither asthma control nor low biomarkers at Week 24	Week 56
Proportion of patients in asthma control at Week 72 among those who demonstrated neither asthma control nor low biomarkers at Week 24	Proportion of patients in asthma control at Week 72 among those who demonstrated neither asthma control nor low biomarkers at Week 24	Week 72
Proportion of patients in clinical remission at Week 56 among those with characteristics of clinical remission at Week 24	Proportion of patients in clinical remission at Week 56 among those with characteristics of clinical remission at Week 24; summarised separately for patients randomised to ICS step-down and for patients randomised to no step-down of ICS.	Week 56
Proportion of patients in clinical remission at Week 72 among those with characteristics of clinical remission at Week 24	Proportion of patients in clinical remission at Week 72 among those with characteristics of clinical remission at Week 24; summarised separately for patients randomised to ICS step-down and for patients randomised to no step-down of ICS.	Week 72
Proportion of patients in clinical remission at both Week 56 and Week 72 among those with characteristics of clinical remission at Week 24	Proportion of patients in clinical remission at both Week 56 and Week 72 among those with characteristics of clinical remission at Week 24; summarised separately for patients randomised to ICS step-down and for patients randomised to no step-down of ICS.	Week 56 and Week 72
Proportion of patients in clinical remission at Week 56 among those who demonstrated neither asthma control nor low biomarkers at Week 24	Proportion of patients in clinical remission at Week 56 among those who demonstrated neither asthma control nor low biomarkers at Week 24	Week 56
Proportion of patients in clinical remission at Week 72 among those who demonstrated neither asthma control nor low biomarkers at Week 24	Proportion of patients in clinical remission at Week 72 among those who demonstrated neither asthma control nor low biomarkers at Week 24	Week 72
Proportion of patients in complete remission at Week 56	Proportion of patients in complete remission at Week 56; summarised separately for patients randomised to ICS step-down, randomised to no ICS step-down, and those who demonstrated neither asthma control nor low biomarkers at Week 24.	Week 56
Proportion of patients in complete remission at Week 72 among those in complete remission at Week 56	Proportion of patients in complete remission at Week 72 among those in complete remission at Week 56; summarised separately for patients randomised to ICS step-down, randomised to no ICS step-down, and those who demonstrated neither asthma control nor low biomarkers at Week 24.	Week 72
Change from Week 24 at Week 56 in: ° Mean monthly maintenance ICS dose ° Mean monthly rescue ICS dose ° Mean monthly total ICS dose (maintenance and rescue doses)	Change from Week 24 at Week 56 in: Mean monthly maintenance ICS dose; Mean monthly rescue ICS dose; Mean monthly total ICS dose (maintenance and rescue doses)	From Week 24 at Week 56
Change from Week 24 at Week 72 in: ° Mean monthly maintenance ICS dose ° Mean monthly rescue ICS dose ° Mean monthly total ICS dose (maintenance and rescue doses)	Change from Week 24 at Week 72 in: Mean monthly maintenance ICS dose; Mean monthly rescue ICS dose; Mean monthly total ICS dose (maintenance and rescue doses)	From Week 24 at Week 72
Cumulative daily ICS dose (maintenance and rescue doses) between Week 24 and Week 56	Cumulative daily ICS dose (maintenance and rescue doses) between Week 24 and Week 56 both summarised separately for patients randomised to ICS step-down, randomised to no ICS step-down, and those who demonstrated neither asthma control nor low biomarkers at Week 24.	Between Week 24 and Week 56
Cumulative daily ICS dose (maintenance and rescue doses) between Week 56 and Week 72	Cumulative daily ICS dose (maintenance and rescue doses) between Week 56 and Week 72 both summarised separately for patients randomised to ICS step-down, randomised to no ICS step-down, and those who demonstrated neither asthma control nor low biomarkers at Week 24.	Between Week 56 and Week 72
Cumulative daily ICS dose (maintenance and rescue doses) between Week 24 and Week 72	Cumulative daily ICS dose (maintenance and rescue doses) between Week 24 and Week 72 both summarised separately for patients randomised to ICS step-down, randomised to no ICS step-down, and those who demonstrated neither asthma control nor low biomarkers at Week 24.	Between Week 24 and Week 72
AAER between Week 0 and Week 24 among all tezepelumab-treated patients	Annualised Asthma Exacerbation Rate between Week 0 and Week 24 among all tezepelumab-treated patients.	Between Week 0 and Week 24
AAER between Week 24 and Week 56	Annualised Asthma Exacerbation Rate between Week 24 and Week 56 summarised separately for patients randomised to ICS step-down, randomised to no ICS step-down, and those who demonstrated neither asthma control nor low biomarkers at Week 24.	Between Week 24 and Week 56
AAER between Week 56 and Week 72	Annualised Asthma Exacerbation Rate between Week 56 and Week 72 summarised separately for patients randomised to ICS step-down, randomised to no ICS step-down, and those who demonstrated neither asthma control nor low biomarkers at Week 24.	Between Week 56 and Week 72
AAER between Week 24 and Week 72	Annualised Asthma Exacerbation Rate between Week 24 and Week 72 summarised separately for patients randomised to ICS step-down, randomised to no ICS step-down, and those who demonstrated neither asthma control nor low biomarkers at Week 24.	Between Week 24 and Week 72
ACQ-5 score and changes from baseline at Week 24 among all tezepelumab-treated patients	ACQ-5 score and changes from baseline at Week 24 among all tezepelumab-treated patients	From baseline at Week 24
ACQ-5 score and changes from Week 24 at Week 56	ACQ-5 score and changes from Week 24 at Week 56; summarised separately for patients randomised to ICS step-down, randomised to no ICS step-down, and those who demonstrated neither asthma control nor low biomarkers at Week 24.	From Week 24 at Week 56
ACQ-5 score and changes from Week 24 at Week 72	ACQ-5 score and changes from Week 24 at Week 72; summarised separately for patients randomised to ICS step-down, randomised to no ICS step-down, and those who demonstrated neither asthma control nor low biomarkers at Week 24.	From Week 24 at Week 72
Proportion of ACQ-5 responders (improvement of≥ 0.5 in ACQ-5 score) from baseline at Week 24 among all tezepelumab-treated patients.	Proportion of ACQ-5 responders (improvement of≥ 0.5 in ACQ-5 score) from baseline at Week 24 among all tezepelumab-treated patients.	From baseline at Week 24
Proportion of ACQ-5 responders (improvement of≥ 0.5 in ACQ-5 score) from Week 24 at Week 56	Proportion of ACQ-5 responders (improvement of≥ 0.5 in ACQ-5 score) from Week 24 at Week 56; summarised separately for patients randomised to ICS step-down, randomised to no ICS step-down, and those who demonstrated neither asthma control nor low biomarkers at Week 24.	From Week 24 at Week 56
Proportion of ACQ-5 responders (improvement of≥ 0.5 in ACQ-5 score) from Week 24 at Week 72	Proportion of ACQ-5 responders (improvement of≥ 0.5 in ACQ-5 score) from Week 24 at Week 72; summarised separately for patients randomised to ICS step-down, randomised to no ICS step-down, and those who demonstrated neither asthma control nor low biomarkers at Week 24.	From Week 24 at Week 72
SGRQ total score and changes from baseline at Week 24 among all tezepelumab-treated patients.	SGRQ total score and changes from baseline at Week 24 among all tezepelumab-treated patients.	From baseline at Week 24
SGRQ total score and changes from Week 24 at Week 56	SGRQ total score and changes from Week 24 at Week 56, summarised separately for patients randomised to ICS step-down, randomised to no ICS step-down, and those who demonstrated neither asthma control nor low biomarkers at Week 24.	From Week 24 at Week 56
SGRQ total score and changes from Week 24 at Week 72	SGRQ total score and changes from Week 24 at Week 72, summarised separately for patients randomised to ICS step-down, randomised to no ICS step-down, and those who demonstrated neither asthma control nor low biomarkers at Week 24.	From Week 24 at Week 72
Proportion of SGRQ responders (improvement of≥ 4 in SGRQ total score) from baseline at Week 24 among all tezepelumab-treated patients.	Proportion of SGRQ responders (improvement of≥ 4 in SGRQ total score) from baseline at Week 24 among all tezepelumab-treated patients	From baseline at Week 24
Proportion of SGRQ responders (improvement of≥ 4 in SGRQ total score) from Week 24 at Week 56	Proportion of SGRQ responders (improvement of≥ 4 in SGRQ total score) from Week 24 at Week 56; summarised separately for patients randomised to ICS step-down, randomised to no ICS step-down, and those who demonstrated neither asthma control nor low biomarkers at Week 24.	From Week 24 at Week 56
Proportion of SGRQ responders (improvement of≥ 4 in SGRQ total score) from Week 24 at Week 72	Proportion of SGRQ responders (improvement of≥ 4 in SGRQ total score) from Week 24 at Week 72; summarised separately for patients randomised to ICS step-down, randomised to no ICS step-down, and those who demonstrated neither asthma control nor low biomarkers at Week 24.	From Week 24 at Week 72
Pre-BD FEV1 actual values and changes from baseline at Week 24 among all tezepelumab-treated patients.	Asthma exacerbations, patient-reported outcomes, and lung function. Pre-BD FEV1 actual values and changes from baseline at Week 24 among all tezepelumab-treated patients.	Baseline at Week 24
Pre-BD FEV1 total score and changes from Week 24 at Week 56	Pre-BD FEV1 total score and changes from Week 24 at Week 56, summarized separately for patients randomised to ICS step-down, randomised to no ICS step-down, and those who demonstrated neither asthma control nor low biomarkers at Week 24 among all tezepelumab-treated patients.	From Week 24 at Week 56
Pre-BD FEV1 total score and changes from Week 24 at Week 72	Pre-BD FEV1 total score and changes from Week 24 at Week 72, summarized separately for patients randomised to ICS step-down, randomised to no ICS step-down, and those who demonstrated neither asthma control nor low biomarkers at Week 24 among all tezepelumab-treated patients.	From Week 24 at Week 72
Proportion of pre-BD FEV1 responders from baseline at Week 24	Proportion of pre-BD FEV1 responders from baseline (defined as patients who achieve either a≥ 5% or ≥ 100 mL improvement from baseline) at Week 24, for all tezepelumab-treated patients	Week 24
Proportion of pre-BD FEV1 responders at Week 56 among those who were pre-BDFEV1 responders at Week 24	Proportion of pre-BD FEV1 responders at Week 56 among those who were pre-BDFEV1 responders at Week 24; summarized separately for patients randomised to ICS step-down, randomised to no ICS step-down, and those who demonstrated neither asthma control nor low biomarkers at Week 24.	Week 56
Proportion of pre-BD FEV1 responders at Week 72 among those who were pre-BDFEV1 responders at Week 24	. Proportion of pre-BD FEV1 responders at Week 72 among those who were pre-BDFEV1 responders at Week 24; summarized separately for patients randomised to ICS step-down, randomised to no ICS step-down, and those who demonstrated neither asthma control nor low biomarkers at Week 24.	Week 72

Collaborators and Investigators

• Sponsor: AstraZeneca
• Collaborators: Fortrea

Study record dates

Study Major Dates

• Study Start (Actual): September 30, 2024
• Primary Completion (Estimated): June 25, 2027
• Study Completion (Estimated): June 25, 2027

Study Registration Dates

• First Submitted: June 10, 2024
• First Submitted That Met QC Criteria: June 19, 2024
• First Posted (Actual): June 25, 2024

Study Record Updates

• Last Update Posted (Actual): March 12, 2026
• Last Update Submitted That Met QC Criteria: March 11, 2026
• Last Verified: March 1, 2026

More Information

Terms related to this study

• Keywords: Clinical remission; Severe Asthma; Asthma control; ICS reduction
• Additional Relevant MeSH Terms: Immune System Diseases; Respiratory Tract Diseases; Lung Diseases; Bronchial Diseases; Lung Diseases, Obstructive; Respiratory Hypersensitivity; Hypersensitivity, Immediate; Hypersensitivity; Asthma; Organic Chemicals; Pharmaceutical Preparations; Carbohydrates; Polycyclic Compounds; Amines; Pregnanes; Steroids; Fused-Ring Compounds; Alcohols; Amino Alcohols; Ethanolamines; Phenethylamines; Ethylamines; Pregnenediones; Pregnenes; Drug Combinations; Sugar Alcohols; Formoterol Fumarate; Budesonide, Formoterol Fumarate Drug Combination; Albuterol; Budesonide; Mannitol; tezepelumab
• Other Study ID Numbers: D5180C00047

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: YES

IPD Plan Description

Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment:

https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. "Yes", indicates that AZ are accepting requests for IPD, but this does not mean all requests will be approved.

• IPD Sharing Time Frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA/PhRMA Data-Sharing Principles. For details of our timelines, please refer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
• IPD Sharing Access Criteria: When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. A Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.
• IPD Sharing Supporting Information Type: STUDY_PROTOCOL; SAP

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: Yes